Cantor Colburn is the #1 Law Firm for Handling Mayo/Myriad Rejections
Recent Federal cases Mayo and Myriad have made it more and more difficult for pharmaceutical, biotech and life sciences companies to obtain patent protection for their innovative new drugs, diagnostic tests, or medical procedures. These difficulties have often hampered the ability to get funding for and to implement new drugs and medical innovations. The ability to obtain strong patent protection, notwithstanding the Mayo and Myriad decisions, has therefore become an important need in the pharma and biotech industries. To that end, Cantor Colburn is pleased to announce that it is the #1 law firm in the country for handling § 101 rejections on biotech, pharma, and life sciences applications according to patent analytics firm Juristat (“The Top Firms for Handling Mayo/Myriad Rejections,” by James Cosgrove, August 14, 2017).